Hikma Pharmaceuticals, the third biggest distributor in the US, will have exclusive rights to sell and distribute the intravenous, opioid-free post-operative pain relief medicine, in the United States.
It is AFT's first licensing agreement for the Maxigesic products in the US market. AFT is still waiting for approval for the tablet and liquid forms of the medication.
AFT managing director Dr Hartley Atkinson said it was a significant step forward for the company.
